Study of POLE and POLD1 mutated tumors
Part of Cancer clinical trials.
This study follows people whose tumors have certain genetic changes in POLE or POLD1. It aims to learn more about these specific tumor mutations and how patients with them may be managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your tumor test shows a POLE gene change in the exonuclease part (exons 9–14) that the study group considers “pathogenic.”
- Or your tumor test shows a POLD1 (PolD1) exonuclease part change (exons 8–12) that the study group considers “pathogenic” (for example, C319Y).
- Your diagnosis is within the study’s timeframe (at or after the cohort launch, or within the prior year).
- You are willing to have your tumor and health data included in the study cohort.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps people and their doctors understand and act on genetic test results, including when results are uncertain. It tests whether a structured approach improves who gets tested in families and helps patients and primary care providers stay up-to-date.
This study looks at how changes (mutations) in a gene called ACTG2 affect the muscles that move food through the gut in children and adults with a rare condition called pediatric intestinal pseudo-obstruction (PIPO). It may help researchers understand the condition better and find new ways to help patients.
This trial looks at a specific genetic change called POLE mutation in women with endometrial cancer that has a high risk of coming back. It may help doctors understand who could benefit from different treatments.
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
This study will look at how certain genetic changes (in the TP53 gene and in chromosome stability) affect endometrial cancer that has a specific molecular profile (pMMR/MSS and no POLE mutation). It aims to understand why these tumors behave the way they do.
Hear when a new Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.